Compare Advance Auto Parts, Inc. (AAP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Summit Therapeutics Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.54 (market cap $3.19B), while Summit Therapeutics Inc trades at $15.16 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 3.8× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AAP | SMMT | |
|---|---|---|
Market Cap | $3.19B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $26.98 |
52-Week Low | $38.75 | $12.55 |
Enterprise Value | $5.47B | $11.39B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.52, down 3.97% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.77 versus $0.39 expected, but profitability remains thin with a net income margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain improvements, as noted in recent news (The Motley Fool, August 2026).
The outlook is cautious; while valuation appears reasonable with a P/S of 0.37 and analysts set a $61.30 consensus target, weak cash flow from operations and high debt pose risks. Investor sentiment is neutral amid restructuring efforts, but margin expansion and successful execution are critical for sustained recovery.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
